

1 **Antimicrobial susceptibility and risk factors for resistance among *Escherichia coli* isolated**  
2 **from canine specimens submitted to a diagnostic laboratory in Indiana, 2010-2019**

3

4 Short title: AMR in *E. coli* isolated from specimens collected from dogs

5

6 John E. Ekakoro<sup>1</sup>, G. Kenitra Hendrix<sup>2</sup>, Lynn F. Guptill<sup>3</sup>, and Audrey Rupple<sup>4\*</sup>

7 <sup>1</sup>Department of Public and Ecosystem Health, College of Veterinary Medicine, Cornell  
8 University, Ithaca, NY, United States of America.

9 <sup>2</sup>Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University,  
10 West Lafayette, IN, United States of America.

11 <sup>3</sup>Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue  
12 University, West Lafayette, IN, United States of America.

13 <sup>4</sup>Department of Population Health Sciences, Virginia-Maryland College of Veterinary Medicine,  
14 Virginia Tech, Blacksburg, VA, United States of America.

15 \*Corresponding author: [arupple@vt.edu](mailto:arupple@vt.edu)

16

17 Key words

18 Antimicrobial resistance, *Escherichia coli*, dogs, multivariable logistic regression.

19

20

## 21 Abstract

22 *Escherichia coli* (*E. coli*) is the most common Gram-negative pathogen isolated in human  
23 infections. Antimicrobial resistant (AMR) *E. coli* originating from dogs may directly or  
24 indirectly cause disease in humans. The objective of this study was to calculate the proportion of  
25 antimicrobial susceptible *E. coli* isolated from canine specimens submitted to the Indiana Animal  
26 Disease Diagnostic Laboratory and to identify temporal patterns of susceptibility among these  
27 isolates. Susceptibility data of 2,738 *E. coli* isolates from dogs from 2010 through 2019 were  
28 used in this study. Proportions of isolates susceptible to the various antimicrobials were  
29 calculated using SAS statistical software and the Cochran-Armitage trend test was used to  
30 investigate the temporal trends in susceptibility. A multivariable binary logistic regression model  
31 was built to investigate the association between host factors and AMR. Overall, 553/2,738  
32 (20.2%) of the isolates were susceptible to 17 of the 27 antimicrobials examined. Of the 2,638  
33 isolates examined for amikacin susceptibility, 2,706 (97.5%) were susceptible, 2,657/2,673  
34 (99.4%) isolates were susceptible to imipenem, and 2,099/2,670 (78.6%) were susceptible to  
35 marbofloxacin. A significant decreasing trend in susceptibility was observed for amoxicillin-  
36 clavulanic acid ( $P<0.0001$ ), ampicillin ( $P<0.0001$ ), Cefazolin ( $P<0.0001$ ), ceftazidime  
37 ( $P=0.0067$ ), chloramphenicol ( $P<0.0001$ ), and orbifloxacin ( $P=0.008$ ). The overall percentage of  
38 AMR isolates (isolates not susceptible to at least one antimicrobial) was 61.7% (1,690/2,738)  
39 and 29.3 % (801/2,738) of isolates were multidrug resistant. Multivariable regression analyses  
40 showed significant associations between AMR and age ( $P=0.0091$ ), breed ( $P=0.0008$ ), and  
41 sample isolation site/source ( $P<0.0001$ ). The decreasing trend in the proportion of isolates  
42 susceptible to several beta-lactam antimicrobials suggests that resistance of *Escherichia coli* in

43 dogs to these antimicrobials could be increasing in Indiana. The decreasing trend in susceptibility  
44 to these drugs could be due to selection pressure from antimicrobial use.

45

## 46 **Introduction**

47 *Escherichia coli*, a member of the ESBL-producing Enterobacteriaceae, is the most  
48 common Gram-negative pathogen isolated in human clinical infections, and antimicrobial  
49 resistant (AMR) *E. coli* pose a threat to both human and animal health [1]. Previous studies have  
50 reported isolation of transmissible AMR *E. coli* in dogs [2]. *E. coli* is the most common cause of  
51 urinary tract infections in humans and dogs and sharing of *E. coli* strains between dogs and  
52 humans can occur [3]. The CDC reported that an estimated 197,400 cases of and 9,100 deaths  
53 occurred due to ESBL-Enterobacteriaceae infections among hospitalized patients in 2017 in the  
54 US [4]. AMR *E. coli* originating from dogs may directly or indirectly cause disease in humans  
55 [5].

56 However, we do not know the total number of cases in which AMR *E. coli* cause disease  
57 or death in dogs in the US. Without this knowledge, we cannot fully understand the role dogs  
58 may play in spreading AMR *E. coli* infections to humans. In addition, understanding the patterns  
59 of antimicrobial susceptibility of bacterial isolates identified from dogs is a critical step in  
60 antimicrobial stewardship and in the containment of AMR within the One Health framework.  
61 The objectives of this study were to: 1) calculate the proportion of antimicrobial susceptible *E.*  
62 *coli* isolates identified in canine specimens submitted to the Indiana Animal Disease Diagnostic  
63 Laboratory (ADDL) from January 1, 2010, through December 1, 2019; 2) identify temporal  
64 trends in susceptibility among these isolates to individual antimicrobials tested; and 3) to identify

65 the temporal patterns and host risk factors for AMR and multidrug resistance (MDR) among  
66 these isolates.

67

## 68 **Materials and Methods**

### 69 **Source of data and ethical approval**

70 The study was exempted from oversight by the Purdue University Institutional Animal  
71 Care and Use Committee (IACUC). We used secondary data obtained from the Indiana ADDL  
72 and informed consent was not required. No field studies or experiments were conducted in this  
73 study, and the study did not directly involve use of animals and posed no risk to clients (animal  
74 owners). Data from *E. coli* isolates phenotypically assessed for AMR from January 1, 2010,  
75 through December 31, 2019, were utilized. The variables extracted from the dataset included: the  
76 age of the dog, breed, sex, geographic location (localized to zip code) of its home, and host  
77 source (anatomic location) of isolation of the pathogen.

78 The antimicrobial susceptibility test (AST) results used in this analysis were obtained  
79 using a dilution-based method that yielded quantitative data (minimum inhibitory concentration)  
80 and the isolates were categorized as susceptible (S), intermediate (I), or resistant (R) based upon  
81 Clinical and Laboratory Standards Institute (CLSI) breakpoints. The susceptibility testing was  
82 performed for 35 drugs: amikacin, amoxicillin, ampicillin, azithromycin, cefazolin, cefovecin,  
83 cefoxitin, cefpodoxime, ceftazidime, ceftiofur, chloramphenicol, chlortetracycline,  
84 clarithromycin, clindamycin, danofloxacin, doxycycline, enrofloxacin, erythromycin, florfenicol,  
85 gentamicin, imipenem, marbofloxacin, neomycin, oxacillin, oxytetracycline, penicillin, rifampin,  
86 spectinomycin, sulfadimethoxine, tetracycline, tiamulin, ticarcillin, ticarcillin-clavulanate,

87 tilmicosin, trimethoprim, tulathromycin, and tylosin. Drugs with complete susceptibility data or  
88 with more than 500 isolates tested were considered in these analyses.

89 Overall, 27 antimicrobials from 10 antimicrobial classes were included in the final  
90 analyses. The antimicrobial classification conformed with the classification described by Riviere  
91 and Papich [6] and the 10 classes included aminoglycosides, the penicillins, cephalosporins and  
92 cephamycins, carbapenems, amphenicols, fluoroquinolones, macrolides, lincosamides,  
93 tetracyclines, and antifolate. All 10 classes belonged to either critically important antimicrobial  
94 classes for human medicine (e.g. aminoglycosides, carbapenems, penicillins) or highly important  
95 antimicrobials (e.g. amphenicols, antifolate) as classified by the World Health Organization  
96 (WHO) [7]. For AMR and MDR determination, drugs known to exhibit intrinsic resistance  
97 phenotypes in Enterobacteriaceae [8] (e.g. penicillin, oxacillin, clindamycin, and erythromycin)  
98 were excluded.

## 99 **Data and statistical analysis**

100 Data cleaning and preparation was performed in Microsoft Excel. The data were assessed  
101 for completeness, duplicates were removed, and only complete records were included in the  
102 analyses. Geographic origins of the samples located to zip code were categorized at the county  
103 and state spatial scales. The state spatial scale categories were further grouped into within  
104 Indiana, out-of-state, and unknown (for those where no geographic origin was reported). The sex  
105 of the dog was categorized as male, female, or intersex regardless of neuter status. Age was  
106 categorized into seven age groups: less than 1 year, 1 to 3 years, over 3 to 6 years, over 6 to 8  
107 years, over 8 to 10years, over 10 to 12years, and greater than 12 years of age as described  
108 previously [9]. We removed one case from the age category due to an implausible age  
109 designation of 95 years.

110 Dog breeds were grouped based on the American Kennel Club (AKC) breed group  
111 classification as described by Conner and colleagues [10]. However, three breeds (English  
112 shepherd, Jack Russel terrier, and Pitbull) that were not listed on the AKC grouping system were  
113 classified based on the United Kennel Club (UKC) grouping [11]. Dogs identified in the dataset  
114 as mixed breed were treated as such in the final grouping. Two breeds (goldendoodle and  
115 cockapoo) that were not yet recognized by any major kennel club were included in the category  
116 mixed. If an animal was identified using a non-specific breed name such as poodle, or schnauzer,  
117 they were categorized as unknown breed. If breed, sex, or age of the dog was not reported and  
118 other data was otherwise complete, it was categorized as “unknown” for the specific category.

119 The anatomic location or specimen source was categorized as: abdominal cavity/fluid, ear  
120 and ocular, feces, respiratory tract, skin, urine and bladder, uterus, vagina and vulva, wounds,  
121 and “all others.” The “all others” contained specimen sources with very small counts or those  
122 with non-specific identities such as fluid, swabs, tissue etc. All AST results reported as “NI” (no  
123 interpretation) were excluded from the analysis. A more conservative approach for categorization  
124 of all AST data reported as susceptible, intermediate, or resistant was adopted for this study as  
125 previously suggested by Sweeney and others [12] and Magiorakos and others [13]. Briefly, the  
126 AST data were grouped into two categories “susceptible” and “not susceptible.” The “not  
127 susceptible” category included the resistant and/or intermediately susceptible isolates. Isolates  
128 that were not susceptible to at least one antimicrobial drug were considered to be AMR isolates  
129 [10] and isolates that were not susceptible to at least one antimicrobial drug in at least three  
130 antimicrobial classes were considered to be MDR [12]. The CLSI guidelines were used in the  
131 analysis of the AST results [14].

## 132 **Descriptive analyses**

133           Statistical analyses were performed in a SAS commercial statistical software.  
134   Frequencies and proportions were used to summarize the data. The Cochran-Armitage trend test  
135   was used to investigate the temporal trends in the data.

### 136   **Univariable and multivariable analysis**

137           Isolates from intersex dogs and from dogs belonging to the foundation stock service  
138   breed group were excluded from the univariable and multivariable analyses due to small counts.  
139   Univariable binary logistic regression was used to investigate the association between  
140   geographic origin of sample and AMR. A further analysis of the associations between host  
141   factors (age, sex, and breed of the dog, specimen source/type and AMR/MDR) were conducted  
142   only for samples with a known in-state address. Variables with a  $p$ -value  $\leq 0.15$  in the  
143   univariable analysis were considered for inclusion in the multivariable model building. A  
144   multivariable binary logistic regression model was built to investigate the association between  
145   host factors and AMR. The backward elimination procedure was used to build the multivariable  
146   model and only statistically significant predictors ( $P \leq 0.05$ ) were retained in the final main  
147   effects multivariable model. In the final model, two-way interactions between age and breed  
148   were assessed based on biological plausibility and standard multiple pairwise comparisons were  
149   obtained using the SAS “LSMEANS” statement. The model fit was assessed using The Hosmer  
150   and Lemeshow Goodness-of-Fit Test. Cluster analysis to discern the spatial patterns of  
151   AMR/MDR was deemed untenable due to small sample sizes in the different counties in Indiana.

## 152   **Results**

### 153   **Sample characteristics**

154 A total of 2,738 *E. coli* isolates were included in the general analysis of these data. Of  
 155 these, 1,641 (59.9%) were isolated from samples obtained from female dogs, 881 (32.2%) from  
 156 male dogs, three (0.1%) were from intersex dogs, and 190 (7%) samples were from dogs that did  
 157 not have sex identified. Most of the samples (n=2,058; 75.2%) were identified using an in-state  
 158 zip code while 275 (10%) were identified as being from out-of-state samples; 405 (14.8%)  
 159 samples had no geographic origin reported. Out-of-state samples came from 18 states: Illinois  
 160 (n=175), Michigan (n=23), Ohio (n=23), Maryland (n=10), Tennessee (n=9), Missouri (n=5),  
 161 Georgia (n=5), West Virginia (n=5), California (n=4), Kentucky (n=4), Florida (n=3), Texas  
 162 (n=2), Pennsylvania (n=2), Virginia (n=1), Wisconsin (n=1), Nebraska (n=1), Alabama (n=1),  
 163 and Arkansas (n=1) (Table 1).

164 **Table 1:** Characteristics of all *Escherichia coli* isolates tested for antimicrobial susceptibility at  
 165 the Indiana Animal Disease Diagnostic Laboratory, from January 2010 to December 2019.

<b>Sample characteristics</b>	<b>Number (%) of isolates</b>
<b>Geographic origin of sample</b>	<b>N=2,738</b>
Indiana	2,058 (75.2)
Out-of-state	275 (10)
Location not recorded	405 (14.8)
<b>Sex</b>	<b>N = 2,738</b>
Female	1,641 (59.9)
Male	881 (32.2)
Intersex	3 (0.1)
Unknown	213 (7.8)
<b>Age of dog (years)</b>	<b>N = 2,737</b>
<1year	208 (7.6)
1-3years	265 (9.7)
>3-6years	440 (16.1)
>6-8years	413 (15.1)
>8-10years	496 (18.1)
>10-12years	447 (16.3)
>12years	408 (14.9)
Unknown	60 (2.2)
<b>Breed Group</b>	<b>N = 2,738</b>
Mixed breed	583 (21.3)



Sporting	565 (20.6)
Working	312 (11.4)
Hound	256 (9.4)
Terrier	256 (9.4)
Toy	252 (9.2)
Herding	222 (8.1)
Non-Sporting	200 (7.3)
Unknown	88 (3.2)
Foundation Stock Service	4 (0.2)
<b>Isolation source</b>	<b>N = 2,738</b>
Abdominal cavity and fluid	77 (2.8)
Ear and Ocular	138 (5)
Feces	170 (6.2)
Respiratory tract	101 (3.7)
Skin	45 (1.6)
Urine and bladder	1676 (61.2)
Uterus, vagina, and vulva	59 (2.2)
Wounds	71 (2.6)
All others	401 (14.7)
<b>Year of sample collection</b>	<b>N = 2,738</b>
2010	206 (7.5)
2011	249 (9.1)
2012	228 (8.3)
2013	232 (8.5)
2014	280 (10.2)
2015	257 (9.4)
2016	310 (11.3)
2017	294 (10.7)
2018	355 (13)
2019	327 (12)

166

## 167 **Proportions and trends in susceptibility to different antimicrobials**

168 Overall, 553 (20.2%) of the isolates were susceptible to 17 of the 27 antimicrobials  
 169 examined. *E. coli* susceptibility to marbofloxacin was 78.6% (2,099/2,670) and ranged from  
 170 83.3% (170/204) susceptible isolates tested in 2010 to 75.7% (234/309) susceptible isolates  
 171 tested in 2019. Overall susceptibility to doxycycline was 74.4% (1,999/2,688) and ranged from  
 172 77.5% (158/204) susceptible isolates tested in 2010 to 72.5 (227/313) susceptible isolates tested  
 173 in 2019 (Table 2). Statistically significant temporal trends were observed among 10 of the 27

174 antimicrobials evaluated (Table 2). A significant ( $P < 0.05$ ) downward (decreasing) trend in  
175 susceptibility was observed for amoxicillin-clavulanic acid, ampicillin, cefalexin, cefazolin,  
176 ceftazidime, cephalothin, chloramphenicol, and orbifloxacin (Table 2).

177 **Table 2:** Trends in antimicrobial susceptibility of *Escherichia coli* isolated from dog specimens tested at the Indiana Animal Disease  
 178 Diagnostic Laboratory, 2010 – 2019.

Antimicrobial class	Antimicrobial	Percentage (number of specimens tested) of susceptible isolates to an antimicrobial										Total	Statistic (Z)-CAT-T	P-values (CAT-T)	
		2010	2011	2012	2013	2014	2015	2016	2017	2018	2019				
Aminoglycosides															
	Amikacin	97.6 (204)	98.8 (248)	95.6 (226)	96.1 (232)	93.9 (277)	98.1 (257)	97.1 (310)	100 (289)	99.2 (354)	97.3 (309)	97.5 (2706)	-2.1528	0.0157	
	Gentamycin	86.4 (206)	93.6 (249)	84.7 (228)	83.2 (232)	87.9 (280)	90.3 (257)	89.4 (310)	92.9 (294)	84.2 (355)	89.3 (327)	88.2 (2738)	-0.3426	0.3660	
Amphenicols	Chloramphenicol	89.2 (203)	91.1 (248)	83.2 (226)	80.6 (232)	86.3 (277)	80.2 (257)	83.9 (310)	82.7 (289)	75.5 (351)	78.8 (217)	82.8 (2610)	4.8084	<.0001	
Antifolate	Trimethoprim	82 (206)	86.8 (249)	75.4 (228)	75.9 (232)	76.8 (280)	81.3 (257)	81.9 (310)	83.6 (293)	74.7 (348)	78.5 (311)	79.6 (2714)	1.2911	0.0983	
Carbapenem	Imipenem	99 (204)	100 (248)	99.1 (226)	99.6 (230)	98.9 (275)	100 (256)	99.7 (306)	99.3 (283)	99.7 (336)	98.7 (309)	99.4 (2673)	0.4271	0.3346	
Cefalosporin/Cefamycin															

	Cefalexin	-	-	-	-	-	-	63.5 (63)	78.3 (281)	61.5 (327)	66 (300)	67.9 (971)	2.1955	0.0141
	Cefazolin	74.3 (202)	75.8 (248)	73 (226)	68.5 (232)	75.1 (277)	73.5 (257)	59.1 (308)	69 (284)	54.6 (339)	51.4 (313)	66.4 (2686)	8.1388	<.0001
	Cefovecin	75 (204)	77 (248)	72.1 (226)	69.6 (230)	78.2 (275)	75.8 (256)	72.9 (306)	84.4 (282)	67.4 (331)	68.9 (309)	74 (2667)	1.4236	0.0773
	Cefoxitin	76.5 (204)	79.8 (248)	74.3 (226)	72.6 (230)	80.7 (275)	82.8 (256)	77 (243)	0	0 (1)	0	77.84 (1683)	-0.8763	0.1904
	Cefpodoxime	74 (204)	76.2 (248)	71.7 (226)	71.3 (230)	77.8 (275)	75.4 (256)	71.9 (306)	84.1 (283)	66.7 (336)	67.6 (309)	73.5 (2673)	1.6614	0.0483
	Ceftazidime	-	-	-	-	-	-	85.7 (63)	89.7 (281)	82.3 (327)	81.3 (300)	84.4 (971)	2.4729	0.0067
	Ceftiofur	75.2 (206)	74.3 (249)	71.5 (228)	66.4 (232)	75.7 (280)	73.5 (257)	73.3 (247)	72.7 (11)	85.7 (21)	79 (19)	73.1 (1750)	-0.3796	0.3521
	Cephalothin	-	76.5 (115)	60.2 (226)	51.1 (141)	-	-	-	0 (2)	0 (9)	7.7 (13)	58.7 (506)	6.7500	<.0001
Penicillins														
	Amoxiclav	72.6 (204)	67.2 (137)	100 (2)	71.4 (91)	69.5 (275)	76.2 (256)	65.6 (299)	48.1 (283)	46.4 (336)	44.4 (288)	60.3 (2171)	9.3130	<.0001

	Ampicillin	59.2 (206)	55.4 (139)	50 (2)	55.3 (94)	53.6 (278)	57.8 (256)	50.7 (306)	37.2 (288)	37.1 (337)	38.2 (275)	47.7 (2183)	7.1012	<.0001
	Penicillin	0 (206)	0 (247)	0 (228)	0 (229)	0 (276)	0 (256)	0 (243)	0 (7)	0 (12)	0 913)	0 (1717)	-	-
	Oxacillin	0.5 (204)	0.8 (248)	2.2 (226)	1.3 (230)	1.5 (275)	0 (256)	1.7 (243)	0 (2)	0 (10)	7.7 (13)	1.2 (1707)	-0.6857	0.2465
	Piperacillin tazobactam	-	-	-	-	-	-	100 (63)	96.4 (281)	97 (326)	97.3 (300)	97.1 (970)	0.2269	0.4103
	Ticarcillin	60.8 (204)	58.1 (248)	54.4 (226)	52.2 (232)	54.9 (277)	58.4 (257)	63.2 (247)	83.3 (6)	52.6 (19)	72.2 (18)	57.6 (1734)	-0.9315	0.1758
	Ticarcillin Clav	72.6 (204)	70.2 (248)	70.8 (226)	64.4 (230)	65.5 (275)	70.3 (256)	67.9 (243)	0	0 (1)	0	68.6 (1683)	1.2077	0.1136
Fluoroquinolones														
	Enrofloxacin	83 (206)	80.3 (249)	74.1 (228)	73 (230)	79.5 (278)	78.9 (256)	76.8 (306)	91.7 (266)	73.3 (326)	73.1 (309)	78.2 (2654)	1.0780	0.1405
	Marbofloxacin	83.3 (204)	81.9 (248)	74.3 (226)	74.4 (230)	80.4 (275)	78.9 (256)	77.5 (306)	88.3 (282)	73.1 (334)	75.7 (309)	78.6 (2670)	1.2731	0.1015
	Orbifloxacin	-	-	-	-	-	-	71.4 (63)	85.4 (280)	72.3 (325)	73 (300)	76.2 (968)	2.3941	0.0083

Lincosamide	Clindamycin	0 (206)	0 (249)	0 (228)	0 (230)	0 (278)	0 (256)	0 (243)	0 (7)	0 (12)	0 (14)	0.06 (1723)	-2.7964	0.0026
Macrolide	Erythromycin	0 (204)	0 (248)	0 (226)	0 (232)	0 (277)	0 (257)	0 (202)	-	-	-	0 (1646)	-	-
Tetracyclines														
	Doxycycline	77.5 (204)	76.6 (248)	72.1 (226)	68.4 (231)	75.8 (277)	73.4 (256)	79.2 (307)	75.9 (286)	72.1 (340)	72.5 (313)	74.4 (2688)	0.5936	0.2764
	Tetracycline	-	-	-	-	-	-	81 (63)	74.4 (285)	70 (327)	72.1 (301)	72.6 (976)	1.3344	0.0910

179

180

181

182

183

184

## 185 **Antimicrobial resistance (AMR) and multi-drug resistance (MDR)**

186           The overall percentage of AMR (isolates not susceptible to at least one antimicrobial) in  
187 isolates was 61.7% (n=1,690) and 29.3 % (801) of isolates were MDR. Of the 1,690 AMR  
188 isolates, 47.4% (801/1,690) were MDR (Table 3). A significant ( $P=<0.0001$ ) upward trend in  
189 AMR was observed while MDR significantly ( $P=0.0083$ ) decreased (Fig.1). Geographic region  
190 of sample origin (e.g., out-of-state versus in-state) was significantly associated with AMR ( $P$   
191  $<.0001$ ). The odds of an isolate being shown to have resistance to at least one antimicrobial were  
192 two times higher in all (combined) out-of-state samples when compared to samples from Indiana  
193 (OR: 2.04, 95% CI: 1.54 - 2.7) and the odds of an isolate being shown to have resistance to at  
194 least one antimicrobial were 1.89 times higher among samples of unreported (unknown) origin  
195 when compared to known Indiana samples (OR: 1.89, 95% CI:1.5 - 2.39).

196

197

198

199

200

201 **Table 3:** Trends in antimicrobial resistance and multidrug resistance among *Escherichia coli* isolated from dog specimens at the  
 202 Indiana Animal Disease Diagnostic Laboratory, 2010 – 2019.

	Percentage (number of specimen tested) of AMR/MDR isolates										Total	Statistic (Z)- CAT-T	P-values (CAT-T)
	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019			
AMR	49 (206)	50.2 (249)	59.2 (228)	63.8 (232)	57.1 (280)	54.5 (257)	60 (310)	72.1 (294)	70.7 (355)	71 (327)	61.7 (2738)	-7.4123	<.0001
MDR	48.5 (101)	52.8 (125)	56.3 (135)	53.4 (148)	43.8 (160)	49.3 (140)	45.2 (186)	39.2 (212)	48.6 (251)	44.4 (232)	47.4 (1690)	2.3959	0.0083

203

204 **Figure 1:** A graphical representation of the temporal trends in antimicrobial resistance and multidrug resistance among *Escherichia*  
 205 *coli* isolated from dog specimens at the Indiana Animal Disease Diagnostic Laboratory, 2010 – 2019.

206

207



208 **Host factors associated with AMR/MDR in Indiana**

209 For all samples from known Indiana addresses, 1,191/2,050 (58.1%) were resistant to at  
 210 least one antimicrobial and 859/2,050 (41.9%) were not resistant to any antimicrobials. Of the  
 211 1,191 AMR isolates, 532 (44.7%) were MDR (Table 4).

212 **Table 4:** The distribution of isolates from Indiana based on host factors and AMR status.

Host factors	Total number (%) of isolates assessed for AMR	Number (%) of AMR isolates		Total number (%) of isolates assessed for MDR	Number (%) of MDR isolates	
		No	Yes		No	Yes
<b>Sex</b>	<b>N = 2050</b>			<b>N=1191</b>		
Female	1239 (60.4)	509 (24.8)	730 (35.6)	730 (61.3)	394 (33.1)	336 (28.2)
Male	617 (30.1)	265 (12.9)	352 (17.2)	352 (29.6)	200 (16.8)	152 (12.8)
Unknown	194 (9.5)	85 (4.2)	109 (5.3)	109 (9.2)	65 (5.5)	44 (3.7)
<b>Age (years)</b>	<b>N = 2050</b>			<b>N=1191</b>		
<1year	177 (8.6)	78 (3.8)	99 (4.8)	99 (8.3)	50 (4.2)	49 (4.1)
1-3years	209 (10.2)	71 (3.5)	138 (6.7)	138 (11.6)	71 (6)	67 (5.6)
>3-6years	319 (15.6)	137 (6.7)	182 (8.9)	182 (15.3)	105 (8.8)	77 (6.5)
>6-8years	330 (16.1)	161 (7.9)	169 (8.2)	169 (14.2)	95 (8)	74 (6.2)
>8-10years	376 (18.3)	166 (8.1)	210 (10.2)	210 (17.6)	132 (11)	78 (6.6)
>10-12years	310 (15.1)	112 (5.5)	198 (9.7)	198 (16.6)	108 (9)	90 (7.6)
>12years	279 (13.6)	114 (5.6)	165 (8)	165 (14)	82 (7)	83 (7)
Unknown	50 (2.4)	20 (0.9)	30 (1.5)	30 (2.5)	16 (1.3)	14 (1.2)
<b>Breed Group</b>	<b>N = 2050</b>			<b>N=1191</b>		
Sporting	457 (22.3)	206 (10.1)	251 (12.2)	251 (21.1)	145 (12.2)	106 (8.9)

Mixed breed	411 (20.1)	178 (8.7)	233 (11.4)	233 (19.6)	128 (10.8)	105 (8.8)
Working	225 (11)	100 (4.9)	125 (6.1)	125 (10.5)	68 (5.7)	57 (4.8)
Toy	195 (9.5)	88 (4.3)	107 (5.2)	107 (9)	67 (5.6)	40 (3.4)
Hound	184 (9)	85 (4.2)	99 (4.8)	99 (8.3)	58 (4.9)	41 (3.4)
Terrier	182 (8.9)	53 (2.6)	129 (6.3)	129 (10.8)	69 (5.8)	60 (5)
Herding	170 (8.3)	56 (2.7)	114 (5.6)	114 (9.6)	50 (4.2)	64 (5.4)
Non-Sporting	147 (7.2)	53 (2.6)	94 (4.6)	94 (7.9)	52 (4.4)	42 (3.5)
Unknown	79 (3.9)	40 (2)	39 (1.9)	39 (3.3)	22 (1.9)	17 (1.4)
<b>Isolation source</b>	<b>N = 2050</b>			<b>N=1191</b>		
Abdominal cavity and fluid	65 (3.2)	26 (1.3)	39 (1.9)	39 (3.3)	26 (2.2)	13 (1.1)
Ear and Ocular	112 (5.5)	42 (2.1)	70 (3.4)	70 (5.9)	43 (3.6)	27 (2.3)
Feces	96 (4.7)	32 (1.6)	64 (3.1)	64 (5.4)	36 (3)	28 (2.4)
Respiratory tract	80 (3.9)	17 (0.8)	63 (3.1)	63 (5.3)	27 (2.3)	36 (3)
Skin	30 (1.4)	9 (0.4)	21 (1)	21 (1.8)	13 (1.1)	8 (0.7)
Urine and bladder	1257 (61.3)	584 (28.5)	673 (32.8)	673 (56.5)	374 (31.4)	299 (25.1)
Uterus, vagina, and vulva	43 (2.1)	23 (1.1)	20 (1)	20 (1.7)	14 (1.2)	6 (0.5)
Wounds	52 (2.5)	13 (0.6)	39 (1.9)	39 (3.3)	17 (1.4)	22 (1.9)
All others	315 (15.4)	113 (5.5)	202 (9.9)	202 (17)	109 (9.2)	93 (7.8)

213

## 214 Univariable logistic regression

215 There was no significant unadjusted association between sex and the outcome of AMR,  
 216 however breed, age, and isolation source had significant associations with AMR (Table 5). There  
 217 were no significant unadjusted associations between the four host factors and MDR (Table 6).

218 **Table 5:** Results of univariable logistic regression models assessing the association of host  
 219 factors with antimicrobial resistance among *Escherichia coli* isolated from dog specimens  
 220 originating from Indiana.

Host factors	Category	OR (95%CI)	P Value
Sex	†Overall	—	0.6338
	Male vs Female	0.93 (0.76 – 1.13)	0.442
	Male vs Unknown	1.04 (0.75 – 1.43)	0.832
	Female vs Unknown	1.12 (0.82 – 1.52)	0.473
Age	†Overall	—	0.0149
	1-3years vs >3-6years	1.46 (1.02 – 2.1)	0.039
	1-3years vs >6-8years	1.85 (1.29 – 2.65)	0.0008
	1-3years vs >8-10years	1.54 (1.08 – 2.18)	0.017
	1-3years vs >10-12years	1.1 (0.76 – 1.59)	0.614
	1-3years vs >12years	1.34 (0.93 – 1.95)	0.121
	1-3years vs Unknown	1.3 (0.69 – 2.44)	0.423
	1-3years vs <1year	1.53 (1.01 – 2.31)	0.043
	>3-6years vs >6-8years	1.27 (0.93 – 1.73)	0.136
	>3-6years vs >8-10years	1.05 (0.78 – 1.42)	0.750
	>3-6years vs >10-12years	0.75 (0.55 – 1.04)	0.081
	>3-6years vs >12years	0.92 (0.66 – 1.27)	0.606
	>3-6years vs Unknown	0.89 (0.48 – 1.63)	0.695
	>3-6years vs <1year	1.05 (0.72 – 1.52)	0.809
	>6-8years vs >8-10years	0.83 (0.62 – 1.12)	0.218
	>6-8years vs >10-12years	0.59 (0.43 – 0.82)	0.001
	>6-8years vs >12years	0.73 (0.53 – 1)	0.05
	>6-8years vs Unknown	0.7 (0.38 – 1.28)	0.248
	>6-8years vs <1year	0.83 (0.57 – 1.19)	0.310
	>8-10years vs >10-12years	0.72 (0.53 – 0.94)	0.034
	>8-10years vs >12years	0.87 (0.64 – 1.2)	0.4
	>8-10years vs Unknown	0.84 (0.46 – 1.54)	0.579
	>8-10years vs <1year	1 (0.7 – 1.43)	0.986
	>10-12years vs >12years	1.22 (0.88 – 1.7)	0.239
>10-12years vs Unknown	1.18 (0.64 – 2.17)	0.598	
>10-12years vs <1year	1.39 (0.96 – 2.03)	0.085	
>12years vs Unknown	0.97 (0.52 – 1.78)	0.909	
>12years vs <1year	1.14 (0.78 – 1.67)	0.499	
Unknown vs <1year	1.18 (0.62 – 2.24)	0.608	
Breed group	†Overall	—	0.0007
	Hound vs Mixed	0.89 (0.63 – 1.26)	0.512
	Hound vs non-Sporting	0.66 (0.42 – 1.02)	0.064
	Hound vs Sporting	0.96 (0.68 – 1.35)	0.797
	Hound vs Terrier	0.48 (0.31 – 0.74)	0.0008
	Hound vs Toy	0.96 (0.64 – 1.44)	0.835
	Hound vs Unknown	1.2 (0.71 – 2.03)	0.509
	Hound vs Working	0.93 (0.63 – 1.38)	0.723
	Hound vs Herding	0.57 (0.37 – 0.88)	0.011
Mixed vs non-Sporting	0.74 (0.5 – 1.09)	0.126	

	Mixed vs Sporting	1.07 (0.82 – 1.41)	0.601
	Mixed vs Terrier	0.54 (0.37 – 0.78)	0.001
	Mixed vs Toy	1.08 (0.76 – 1.52)	0.673
	Mixed vs Unknown	1.34 (0.83 – 2.18)	0.231
	Mixed vs Working	1.05 (0.76 – 1.45)	0.783
	Mixed vs Herding	0.64 (0.44 – 0.94)	0.021
	Non-Sporting vs Sporting	1.46 (0.99 – 2.14)	0.055
	Non-Sporting vs Terrier	0.73 (0.46 – 1.16)	0.182
	Non-Sporting vs Toy	1.46 (0.94 – 2.26)	0.092
	Non-Sporting vs Unknown	1.82 (1.04 – 3.17)	0.035
	Non-Sporting vs Working	1.42 (0.93 – 2.18)	0.109
	Non-Sporting vs Herding	0.87 (0.55 – 1.39)	0.561
	Sporting vs Terrier	0.5 (0.35 – 0.72)	0.0002
	Sporting vs Toy	1 (0.72 – 1.4)	0.99
	Sporting vs Unknown	1.25 (0.78 – 2.02)	0.361
	Sporting vs Working	0.98 (0.71 – 1.34)	0.876
	Sporting vs Herding	0.6 (0.41 – 0.87)	0.006
	Terrier vs Toy	2 (1.31 – 3.07)	0.001
	Terrier vs Unknown	2.5 (1.45 – 4.3)	0.001
	Terrier vs Working	1.95 (1.29 – 2.95)	0.002
	Terrier vs Herding	1.2 (0.76 – 1.88)	0.439
	Toy vs Unknown	1.25 (0.74 – 2.11)	0.408
	Toy vs Working	0.97 (0.66 – 1.43)	0.888
	Toy vs Herding	0.6 (0.39 – 0.92)	0.018
	Unknown vs Working	0.78 (0.47 – 1.3)	0.343
	Unknown vs Herding	0.48 (0.28 – 0.83)	0.008
	Working vs Herding	0.61 (0.41 – 0.93)	0.02
Sample source/sample type	†Overall	—	<.0001
	Ear & ocular vs Feces	0.83 (0.47 – 1.48)	0.532
	Ear & ocular vs Respiratory tract	0.45 (0.23 – 0.87)	0.017
	Ear & ocular vs Skin	0.71 (0.3 – 1.7)	0.448
	Ear & ocular vs Urine & bladder	1.45 (0.97 – 2.15)	0.069
	Ear & ocular vs Uterus, vagina, vulva	1.92 (0.94 – 3.9)	0.073
	Ear & ocular vs Wounds	0.56 (0.27 – 1.16)	0.117
	Ear & ocular vs All others	0.93 (0.6 – 1.46)	0.758
	Ear & ocular vs Abdominal cavity/fluid	1.1 (0.59 – 2.08)	0.742
	Feces vs Respiratory tract	0.54 (0.27 – 1.07)	0.077
	Feces vs Skin	0.86 (0.35 – 2.09)	0.734
	Feces vs Urine & bladder	1.74 (1.12 – 2.69)	0.014
	Feces vs Uterus, vagina, vulva	2.3 (1.1 – 4.79)	0.026
	Feces vs Wounds	0.67 (0.31 – 1.42)	0.294
	Feces vs All others	1.12 (0.69 – 1.81)	0.649
	Feces vs Abdominal cavity/fluid	1.3 (0.69 – 2.56)	0.389

	Respiratory tract vs Skin	1.59 (0.62 – 4.09)	0.338
	Respiratory tract vs Urine & bladder	3.2 (1.86 – 5.56)	<.0001
	Respiratory tract vs Uterus, vagina, vulva	4.26 (1.91 – 9.52)	0.0004
	Respiratory tract vs wounds	1.24 (0.54 – 2.82)	0.616
	Respiratory tract vs all others	2.07 (1.16 – 3.71)	0.014
	Respiratory tract vs Abdominal cavity/fluid	2.47 (1.19 – 5.13)	0.015
	Skin vs Urine & bladder	2.03 (0.92 – 4.46)	0.08
	Skin vs Uterus, vagina, vulva	2.68 (1 – 7.18)	0.049
	Skin vs Wounds	0.78 (0.29 – 2.12)	0.623
	Skin vs All others	1.31 (0.58 – 2.95)	0.521
	Skin vs Abdominal cavity/fluid	1.56 (0.62 – 3.92)	0.349
	Urine & bladder vs Uterus, vagina, vulva	1.33 (0.72 – 2.44)	0.365
	Urine & bladder vs Wounds	0.38 (0.2 – 0.73)	0.003
	Urine & bladder vs All others	0.65 (0.5 – 0.83)	0.0008
	Urine & bladder vs Abdominal cavity/fluid	0.77 (0.46 – 1.28)	0.31
	Uterus, vagina, vulva vs Wounds	0.29 (0.12 – 0.69)	0.005
	Uterus, vagina, vulva vs All others	0.49 (0.26 – 0.92)	0.028
	Uterus, vagina, vulva vs Abdominal cavity/fluid	0.58 (0.27 – 1.26)	0.17
	Wounds vs All others	1.68 (0.86 – 3.28)	0.129
	Wounds vs Abdominal cavity/fluid	2 (0.9 – 4.45)	0.09
	All others vs Abdominal cavity/fluid	1.19 (0.69 – 2.06)	0.53
†Overall = overall effect of host factor on AMR			

221

222 **Table 6:** Results of univariable logistic regression models assessing the association of host

223 factors with multi-drug resistance among *Escherichia coli* isolated from dog specimens

224 originating from Indiana.

Host factors	Category	OR (95%CI)	P Value
Sex	†Overall	—	0.4330
	Male vs Female	0.89 (0.69 – 1.15)	0.378
	Male vs Unknown	1.12 (0.73 – 1.74)	0.604

	Female vs Unknown	1.26 (0.84 – 1.9)	0.269
Age	†Overall	—	0.2377
	1-3years vs >3-6years	1.29 (0.83 – 2.01)	0.267
	1-3years vs >6-8years	1.21 (0.77 – 1.9)	0.405
	1-3years vs >8-10years	1.6 (1.03 – 2.47)	0.035
	1-3years vs >10-12years	1.13 (0.73 – 1.75)	0.576
	1-3years vs >12years	0.93 (0.59 – 1.47)	0.761
	1-3years vs Unknown	1.08 (0.49 – 2.38)	0.852
	1-3years vs <1year	0.96 (0.58 – 1.6)	0.886
	>3-6years vs >6-8years	0.94 (0.62 – 1.44)	0.78
	>3-6years vs >8-10years	1.24 (0.83 – 1.86)	0.297
	>3-6years vs >10-12years	0.88 (0.59 – 1.32)	0.537
	>3-6years vs >12years	0.72 (0.47 – 1.11)	0.136
	>3-6years vs Unknown	0.84 (0.39 – 1.82)	0.655
	>3-6years vs <1year	0.75 (0.46 – 1.22)	0.248
	>6-8years vs >8-10years	1.32 (0.87 – 1.99)	0.19
	>6-8years vs >10-12years	0.94 (0.62 – 1.41)	0.749
	>6-8years vs >12years	0.77 (0.5 – 1.18)	0.233
	>6-8years vs Unknown	0.89 (0.41 – 1.94)	0.77
	>6-8years vs <1year	0.8 (0.48 – 1.31)	0.366
	>8-10years vs >10-12years	0.71 (0.48 – 1.05)	0.089
	>8-10years vs >12years	0.58 (0.39 – 0.88)	0.011
	>8-10years vs Unknown	0.68 (0.31 – 1.46)	0.318
	>8-10years vs <1year	0.6 (0.37 – 0.98)	0.04
	>10-12years vs >12years	0.82 (0.54 – 1.25)	0.357
	>10-12years vs Unknown	0.95 (0.44 – 2.06)	0.901
>10-12years vs <1year	0.85 (0.52 – 1.38)	0.511	
>12years vs Unknown	1.16 (0.53 – 2.52)	0.714	
>12years vs <1year	1.03 (0.63 – 1.7)	0.899	
Unknown vs <1year	0.89 (0.39 – 2.02)	0.786	
Breed group	†Overall	—	0.3
	Hound vs Mixed	0.86 (0.54 – 1.39)	0.54
	Hound vs non-Sporting	0.88 (0.5 – 1.55)	0.647
	Hound vs Sporting	0.97 (0.6 – 1.55)	0.889
	Hound vs Terrier	0.81 (0.48 – 1.38)	0.443
	Hound vs Toy	1.18 (0.68 – 2.07)	0.554
	Hound vs Unknown	0.92 (0.43 – 1.93)	0.816
	Hound vs Working	0.84 (0.5 – 1.44)	0.531
	Hound vs Herding	0.55 (0.32 – 0.95)	0.033
	Mixed vs non-Sporting	1.02 (0.63 – 1.64)	0.95
	Mixed vs Sporting	1.12 (0.78 – 1.61)	0.53
	Mixed vs Terrier	0.94 (0.61 – 1.45)	0.791
	Mixed vs Toy	1.37 (0.86 – 2.2)	0.184
	Mixed vs Unknown	1.06 (0.54 – 2.1)	0.864
	Mixed vs Working	0.98 (0.63 – 1.51)	0.923

	Mixed vs Herding	0.64 (0.41 – 1.01)	0.053
	Non-Sporting vs Sporting	1.11 (0.69 – 1.78)	0.682
	Non-Sporting vs Terrier	0.93 (0.55 – 1.58)	0.786
	Non-Sporting vs Toy	1.35 (0.77 – 2.38)	0.294
	Non-Sporting vs Unknown	1.05 (0.49 – 2.22)	0.908
	Non-Sporting vs Working	0.96 (0.56 – 1.65)	0.892
	Non-Sporting vs Herding	0.63 (0.36 – 1.09)	0.101
	Sporting vs Terrier	0.84 (0.55 – 1.29)	0.426
	Sporting vs Toy	1.22 (0.77 – 1.95)	0.393
	Sporting vs Unknown	0.95 (0.48 – 1.87)	0.873
	Sporting vs Working	0.87 (0.57 – 1.34)	0.535
	Sporting vs Herding	0.57 (0.37 – 0.89)	0.014
	Terrier vs Toy	1.46 (0.86 – 2.46)	0.158
	Terrier vs Unknown	1.13 (0.55 – 2.32)	0.748
	Terrier vs Working	1.04 (0.63 – 1.7)	0.884
	Terrier vs Herding	0.68 (0.41 – 1.13)	0.135
	Toy vs Unknown	0.77 (0.37 – 1.63)	0.497
	Toy vs Working	0.71 (0.42 – 1.21)	0.207
	Toy vs Herding	0.47 (0.27 – 0.8)	0.006
	Unknown vs Working	0.92 (0.45 – 1.9)	0.826
	Unknown vs Herding	0.6 (0.29 – 1.26)	0.177
	Working vs Herding	0.66 (0.39 – 1.09)	0.104
Sample source/sample type	†Overall	—	0.1856
	Ear & ocular vs Feces	0.81 (0.41 – 1.61)	0.543
	Ear & ocular vs Respiratory tract	0.47 (0.24 – 0.94)	0.033
	Ear & ocular vs Skin	1.02 (0.37 – 2.78)	0.969
	Ear & ocular vs Urine & bladder	0.79 (0.47 – 1.3)	0.348
	Ear & ocular vs Uterus, vagina, vulva	1.47 (0.5 – 4.27)	0.485
	Ear & ocular vs Wounds	0.49 (0.22 – 1.08)	0.075
	Ear & ocular vs All others	0.74 (0.42 – 1.28)	0.279
	Ear & ocular vs Abdominal cavity/fluid	1.26 (0.55 – 2.86)	0.587
	Feces vs Respiratory tract	0.58 (0.29 – 1.18)	0.132
	Feces vs Skin	1.26 (0.46 – 3.47)	0.649
	Feces vs Urine & bladder	0.97 (0.58 – 1.63)	0.917
	Feces vs Uterus, vagina, vulva	1.81 (0.62 – 5.32)	0.278
	Feces vs Wounds	0.6 (0.27 – 1.34)	0.214
	Feces vs All others	0.91 (0.52 – 1.61)	0.749
	Feces vs Abdominal cavity/fluid	1.56 (0.68 – 3.56)	0.296
	Respiratory tract vs Skin	2.18 (0.79 – 5.96)	0.134
	Respiratory tract vs Urine & bladder	1.67 (0.99 – 2.81)	0.055
	Respiratory tract vs Uterus, vagina, vulva	3.1 (1.06 – 9.15)	0.039

	Respiratory tract vs wounds	1.03 (0.46 – 2.31)	0.942
	Respiratory tract vs all others	1.56 (0.88 – 2.77)	0.125
	Respiratory tract vs Abdominal cavity/fluid	2.67 (1.16 – 6.13)	0.021
	Skin vs Urine & bladder	0.77 (0.32 – 1.88)	0.566
	Skin vs Uterus, vagina, vulva	1.44 (0.39 – 5.27)	0.586
	Skin vs Wounds	0.48 (0.16 – 1.42)	0.179
	Skin vs All others	0.72 (0.29 – 1.82)	0.488
	Skin vs Abdominal cavity/fluid	1.23 (0.41 – 3.71)	0.713
	Urine & bladder vs Uterus, vagina, vulva	1.87 (0.71 – 4.91)	0.207
	Urine & bladder vs Wounds	0.62 (0.32 – 1.18)	0.147
	Urine & bladder vs All others	0.94 (0.68 – 1.29)	0.686
	Urine& bladder vs Abdominal cavity/fluid	1.6 (0.81 – 3.17)	0.178
	Uterus, vagina, vulva vs Wounds	0.33 (0.11 – 1.04)	0.059
	Uterus, vagina, vulva vs All others	0.5 (0.19 – 1.36)	0.175
	Uterus, vagina, vulva vs Abdominal cavity/fluid	0.86 (0.27 – 2.75)	0.796
	Wounds vs All others	1.52 (0.76 – 3.01)	0.237
	Wounds vs Abdominal cavity/fluid	2.59 (1.03 – 6.49)	0.043
	All others vs Abdominal cavity/fluid	1.71 (0.83 – 3.51)	0.146
†Overall = overall effect of host factor on AMR			

225

## 226 **Adjusted associations**

227 All host factors found to be widely significantly associated ( $P \leq 0.15$ ) with AMR in the  
 228 univariable logistic regression models were included in the multivariable logistic regression  
 229 analyses. Thus, for AMR, age ( $P=0.0149$ ), breed ( $P=0.0007$ ) and sample source/sample type  
 230 ( $P<.0001$ ) were included in the multivariable model. All three host factors were retained in the  
 231 final multivariable model (Table 7) which showed significant associations between AMR and  
 232 age ( $P=0.009$ ), breed ( $P=0.0007$ ), and sample isolation site/source ( $P<0.0001$ ). The Hosmer and  
 233 Lemeshow Goodness-of-Fit Test showed that this model best fit these data ( $\chi^2= 8.05$ ,  $DF=8$ ,



234  $P=0.429$ ). The multivariable model showed that controlling for breed and specimen source, the  
 235 odds of AMR in isolates from dogs aged 1 to 3 years were 1.63 times as high as the AMR odds  
 236 in isolates from dogs aged between 6 and 8 years and isolates from dogs aged greater than 10  
 237 years were more likely to be antimicrobial resistant than those isolated from other age groups.  
 238 Based on the non-significant unadjusted associations (using a liberal  $\alpha = 0.15$ ), a multivariable  
 239 model for the association between the host factors and MDR was not built.

240 **Table 7:** Multivariable binary logistic regression model of the associations between host factors  
 241 and antimicrobial resistance among *Escherichia coli* isolated from samples from Indiana.

Host factors	Category	OR (95% CI)	P Value
Age	†Overall	—	0.009
	1-3years vs >3-6years	1.31 (0.9 – 1.9)	0.159
	1-3years vs >6-8years	1.63 (1.13 – 2.36)	0.009
	1-3years vs >8-10years	1.35 (0.94 – 1.94)	0.103
	1-3years vs >10-12years	0.89 (0.61 – 1.3)	0.543
	1-3years vs >12years	1.08 (0.73 – 1.59)	0.718
	1-3years vs Unknown	1.14 (0.59 – 2.2)	0.697
	1-3years vs <1year	1.5 (0.98 – 2.29)	0.064
	>3-6years vs >6-8years	1.25 (0.91 – 1.72)	0.167
	>3-6years vs >8-10years	1.04 (0.76 – 1.41)	0.83
	>10-12years vs >3-6years	1.47 (1.06 – 2.05)	0.023
	>3-6years vs >12years	0.82 (0.58 – 1.16)	0.264
	>3-6years vs Unknown	0.87 (0.46 – 1.64)	0.671
	>3-6years vs <1year	1.15 (0.78 – 1.69)	0.493
	>6-8years vs >8-10years	0.83 (0.61 – 1.12)	0.221
	>10-12years vs >6-8years	1.84 (1.33 – 2.55)	0.0003
	>12years vs >6-8years	1.52 (1.09 – 2.12)	0.014
	>6-8years vs Unknown	0.7 (0.37 – 1.31)	0.26
	>6-8years vs <1year	0.92 (0.62 – 1.35)	0.654
	>10-12years vs >8-10years	1.52 (1.11 – 2.1)	0.009
	>8-10years vs >12years	0.8 (0.58 – 1.1)	0.165
	>8-10years vs Unknown	0.84 (0.45 – 1.57)	0.591
	>8-10years vs <1year	1.11 (0.76 – 1.62)	0.598
	>10-12years vs >12years	1.21 (0.86 – 1.7)	0.271
>10-12years vs Unknown	1.28 (0.68 – 2.42)	0.442	
>10-12years vs <1year	1.69 (1.13 – 2.51)	0.01	
>12years vs Unknown	1.06 (0.56 – 2.01)	0.858	

	>12years vs <1year	1.39 (0.93 – 2.09)	0.11
	Unknown vs <1year	1.31 (0.68 – 2.55)	0.422
Breed group	†Overall	—	0.0007
	Hound vs Mixed	0.92 (0.64 – 1.31)	0.632
	Hound vs non-Sporting	0.67 (0.42 – 1.05)	0.081
	Hound vs Sporting	0.94 (0.66 – 1.35)	0.749
	Hound vs Terrier	0.47 (0.3 – 0.73)	0.0008
	Hound vs Toy	0.97 (0.64 – 1.46)	0.865
	Hound vs Unknown	1.3 (0.75 – 2.25)	0.343
	Hound vs Working	0.93 (0.62 – 1.41)	0.742
	Herding vs Hound	1.68 (1.08 – 2.63)	0.022
	Mixed vs non-Sporting	0.73 (0.49 – 1.08)	0.114
	Mixed vs Sporting	1.03 (0.78 – 1.36)	0.832
	Terrier vs Mixed	1.95 (1.33 – 2.86)	0.0006
	Mixed vs Toy	1.05 (0.74 – 1.49)	0.772
	Mixed vs Unknown	1.42 (0.87 – 2.34)	0.165
	Mixed vs Working	1.02 (0.73 – 1.43)	0.913
	Mixed vs Herding	0.65 (0.44 – 0.95)	0.027
	Non-Sporting vs Sporting	1.42 (0.96 – 2.1)	0.079
	Non-Sporting vs Terrier	0.71 (0.44 – 1.13)	0.15
	Non-Sporting vs Toy	1.45 (0.93 – 2.28)	0.104
	Non-Sporting vs Unknown	1.96 (1.11 – 3.47)	0.021
	Non-Sporting vs Working	1.4 (0.91 – 2.17)	0.127
	Non-Sporting vs Herding	0.89 (0.56 – 1.43)	0.642
	Terrier vs Sporting	2.01 (1.38 – 2.93)	0.0003
	Sporting vs Toy	1.02 (0.72 – 1.44)	0.9
	Sporting vs Unknown	1.38 (0.84 – 2.26)	0.2
	Sporting vs Working	0.99 (0.71 – 1.38)	0.949
	Sporting vs Herding	0.63 (0.43 – 0.92)	0.016
	Terrier vs Toy	2.06 (1.33 – 3.2)	0.001
	Terrier vs Unknown	2.78 (1.59 – 4.86)	0.0003
	Terrier vs Working	1.99 (1.3 – 3.06)	0.002
	Terrier vs Herding	1.27 (0.8 – 2.01)	0.317
	Toy vs Unknown	1.35 (0.79 – 2.32)	0.275
	Toy vs Working	0.97 (0.65 – 1.44)	0.872
	Herding vs Toy	1.62 (1.05 – 2.51)	0.03
Unknown vs Working	0.72 (0.42 – 1.22)	0.22	
Unknown vs Herding	0.46 (0.26 – 0.8)	0.006	
Herding vs Working	1.57 (1.03 – 2.4)	0.037	
Sample source/sample type	†Overall	—	<.0001
	Ear & ocular vs Feces	0.8 (0.45 – 1.43)	0.446
	Respiratory tract vs Ear & ocular	2.2 (1.12 – 4.34)	0.023
	Ear & ocular vs Skin	0.9 (0.37 – 2.18)	0.814
	Ear & ocular vs Urine & bladder	1.59 (1.06 – 2.39)	0.026

Ear & ocular vs Uterus, vagina, vulva	1.91 (0.92 – 3.94)	0.081
Ear & ocular vs Wounds	0.64 (0.3 – 1.35)	0.24
Ear & ocular vs All others	0.97 (0.61 – 1.53)	0.889
Ear & ocular vs Abdominal cavity/fluid	1.24 (0.66 – 2.35)	0.504
Feces vs Respiratory tract	0.57 (0.28 – 1.15)	0.115
Feces vs Skin	1.13 (0.46 – 2.79)	0.795
Feces vs Urine & bladder	1.99 (1.27 – 3.13)	0.003
Feces vs Uterus, vagina, vulva	2.39 (1.13 – 5.04)	0.022
Feces vs Wounds	0.8 (0.37 – 1.73)	0.573
Feces vs All others	1.22 (0.74 – 1.99)	0.44
Feces vs Abdominal cavity/fluid	1.56 (0.8 – 3.04)	0.191
Respiratory tract vs Skin	1.98 (0.75 – 5.2)	0.166
Respiratory tract vs Urine & bladder	3.5 (1.99 – 6.13)	<.0001
Respiratory tract vs Uterus, vagina, vulva	4.2 (1.84 – 9.56)	0.0006
Respiratory tract vs wounds	1.41 (0.61 – 3.26)	0.425
Respiratory tract vs all others	2.13 (1.18 – 3.86)	0.013
Respiratory tract vs Abdominal cavity/fluid	2.74 (1.3 – 5.77)	0.008
Skin vs Urine & bladder	1.77 (0.79 – 3.94)	0.165
Skin vs Uterus, vagina, vulva	2.12 (0.78 – 5.77)	0.141
Skin vs Wounds	0.71 (0.26 – 1.96)	0.511
Skin vs All others	1.08 (0.47 – 2.46)	0.861
Skin vs Abdominal cavity/fluid	1.38 (0.54 – 3.54)	0.499
Urine & bladder vs Uterus, vagina, vulva	1.2 (0.64 – 2.24)	0.566
Wounds vs Urine & bladder	2.49 (1.3 – 4.74)	0.006
Urine & bladder vs All others	0.61 (0.47 – 0.8)	0.0003
Urine & bladder vs Abdominal cavity/fluid	0.78 (0.47 – 1.32)	0.356
Wounds vs Uterus, vagina, vulva	2.98 (1.24 – 7.2)	0.015
Uterus, vagina, vulva vs All others	0.51 (0.26 – 0.98)	0.042
Uterus, vagina, vulva vs Abdominal cavity/fluid	0.65 (0.3 – 1.44)	0.29
Wounds vs All others	1.52 (0.77 – 2.98)	0.23
Wounds vs Abdominal cavity/fluid	1.95 (0.87 – 4.37)	0.107
All others vs Abdominal cavity/fluid	1.28 (0.74 – 2.24)	0.378
†Overall = overall effect of host factor on AMR		

## 243 Discussion

244 In the present study, we found significant trends in susceptibility, total AMR and MDR in  
245 canine *E. coli* isolates, and we identified significant associations between AMR and dog age,  
246 breed, and the source of the specimens. We found significant declines in the susceptibility to  
247 cefalexin, cefazolin, and cephalothin which are 1<sup>st</sup> generation cephalosporins and to cefpodoxime  
248 and ceftazidime which are 3<sup>rd</sup> generation cephalosporins. Similar to our study, a previous study  
249 found high level resistance to commonly used beta lactams (penicillins, cephalosporins) in dogs  
250 in the United States [15]. Particularly, 39.7% of all the isolates in the present study were not  
251 susceptible to amoxicillin-clavulanic acid and 52.3% were not susceptible to ampicillin, and  
252 susceptibility to these drugs significantly declined over time. Similar to our findings, a previous  
253 study by Thungrat and others reported high-level resistance (45%) to amoxicillin-clavulanic acid  
254 and 52.7% to ampicillin among *E. coli* isolated from dogs in the United States [15]. It is  
255 important to note that amoxicillin-clavulanic acid is the most commonly prescribed antimicrobial  
256 in many veterinary practices [16–18] and ampicillin is also commonly used to treat bacterial  
257 infections in dogs [15]. Therefore, the decreasing trend in the proportion of isolates susceptible  
258 to antimicrobials in the beta lactam group in this study could be due to selection pressure from  
259 antimicrobial use. For the fluoroquinolone drugs, 21.8% of all the isolates tested were not  
260 susceptible to enrofloxacin. A previous study conducted in the northeastern US reported that  
261 nearly 20% of the *E. coli* isolated from dogs during the period 2004 - 2011 were resistant to  
262 enrofloxacin [19]. Also, among the fluoroquinolone antimicrobials, the decline in susceptibility  
263 to orbifloxacin observed could be associated with selection pressure from antimicrobial use.

264 The level of AMR in *E. coli* is a good indicator of AMR in bacterial pathogens of dogs  
265 and other species [20,21] because of its ubiquitous nature and its ability to act as a reservoir of

266 AMR genes that can transferred to other pathogens through horizontal gene transfer [22].  
267 Additionally, AMR in *E. coli* is suggested to be a good sentinel of the effects of selective  
268 pressure from AMU [23]. Therefore, the significant increase in AMR *E. Coli* observed in this  
269 study could be an indicator of an increasing AMR trend among other pathogenic bacteria in the  
270 dog populations served by this diagnostic laboratory. This suggests for a need for more concerted  
271 efforts in controlling AMR in small animal practice through judicious AMU. The decreasing  
272 trend observed for MDR could have resulted from the varying susceptibility trends observed for  
273 individual antimicrobials where some individual drugs had decreasing susceptibility trends while  
274 others had increasing susceptibility. Corner and others attributed similar decreases in MDR in  
275 *Staphylococcus spp.* to variability in individual drug susceptibility [10].

276 The total lack of susceptibility to clindamycin and erythromycin observed is due to  
277 intrinsic resistance [8]. Enterobacteriaceae such as *E. coli* are known to be intrinsically resistant  
278 to lincosamides and macrolides such as clindamycin and erythromycin respectively. This  
279 information is provided here to guide veterinary clinicians who might find it useful when  
280 deciding which antimicrobial to select.

281 We found high susceptibility of the isolates to amikacin (97.6% susceptibility in 2010  
282 and 97.3% in 2019) and observed a significant increase in susceptibility to this drug. Similar to  
283 our findings, a previous study that investigated the antimicrobial susceptibility patterns of *E. coli*  
284 in dogs and cats in the United States found only 0.7% of 2,390 canine *E. coli* isolates were  
285 resistant to amikacin [15]. Another study in Canada found 93.8% of 3,364 canine *E. coli* isolates  
286 were susceptible to Amikacin [17]. The high susceptibility and increasing trend in susceptibility  
287 to amikacin observed in the present study could be indicative of limited use of this antimicrobial  
288 in small animal practice in Indiana. The limited use of this drug could be associated with

289 concerns about aminoglycoside toxicity. Similar to the results in amikacin, we found a near  
290 perfect susceptibility to imipenem suggesting that imipenem is rarely used in the treatment of  
291 bacterial diseases of dogs in Indiana. Imipenem belongs to the carbapenem antimicrobial class  
292 and is used in the treatment of multidrug resistant Enterobacteriaceae e.g. *E. coli* [24]. Perhaps  
293 this finding could reflect adherence by small animal clinicians to the guidelines for carbapenem  
294 use provided by the International Society for Companion Animal Infectious Diseases (ISCAID).  
295 The ISCAID recommends that carbapenems should be used only if the pathogen is proven to be  
296 resistant to all other reasonable antimicrobial options and susceptibility to the carbapenem  
297 chosen is documented [24].

298         In the present study, 61% of the *E. coli* isolates were found in specimens submitted from  
299 the urinary tract. This finding is similar to the findings in previous studies in the U.S. where most  
300 of the *E. coli* were isolated from the urinary tract [15,19]. This suggests that urinary tract  
301 infections could have been the major reason for canine sample submission to this laboratory.  
302 However, 3.7% of the *E. coli* isolates were from the respiratory tract and these respiratory tract  
303 isolates were more likely to be antimicrobial resistant than those isolated from the urogenital  
304 tract (urine, bladder, uterus, vagina, and vulva), and the abdominal cavity. This is in contrast to a  
305 previous study in the north eastern United States which reported that multidrug resistance was  
306 more likely among urinary *E. coli* than in *E. coli* isolated from other canine body sites [19]. *E*  
307 *.coli* is known to be involved in respiratory tract infections in dogs and has been isolated from  
308 respiratory tract samples [25,26]. Possibly, the higher AMR observed in the respiratory tract  
309 isolates in our study could be due to selection pressure resulting from AMU targeting respiratory  
310 tract infections in these dogs. There is a need for an in-depth study of AMR among *E. coli*  
311 causing respiratory disease.

312 In the present study, we found that *E. coli* isolated from dogs older than 10 years were  
313 more likely to be resistant to antimicrobials when compared to *E. coli* isolated from younger  
314 dogs after controlling for breed and specimen source. This finding could be due to selection  
315 pressure from prior/routine antimicrobial use in dogs in this category since dogs older than 10  
316 years are more likely to have been treated with antimicrobials multiple times when compared to  
317 younger dogs. Previous studies found prior use of antimicrobials was a risk factor for AMR in  
318 dogs [27,28] and AMR *E. coli* was common among vet-visiting dogs [29]. Specifically, prior  
319 exposure to some antimicrobials such as fluoroquinolones may select for antimicrobial resistant  
320 *E. coli* in dogs that could persist long after antimicrobial therapy [30,31]. Recurrent *E. coli*  
321 infections are possible because *E. coli* possess multiple adaptations for survival and persistence  
322 in the host [32]. Dogs older than 10 years are generally considered geriatric and are likely to  
323 have weakened immune systems due to old age, and as a result, could be susceptible to frequent  
324 infections necessitating antimicrobial use. Also, selection pressure from prior AMU could be the  
325 reason why isolates from dogs aged 1 to 3 years were 1.63 times more likely to be antimicrobial  
326 resistant when compared to those from dogs between 6 and 8 years of age. From a public health  
327 standpoint, the role of dogs aged older than 10 years and those aged 1 to 3 years in the  
328 dissemination of AMR *E. coli* needs to be further investigated. The implications are that humans  
329 in close contact with dogs in these age groups would be at a higher risk of exposure to AMR *E.*  
330 *coli*. Veterinarians should be made aware of the potential role of dogs aged older than 10 years  
331 and those aged 1 to 3 years in the spread of AMR *E. coli*. Generally, owners of older dogs need  
332 to be aware of the AMR *E. coli* risk in older dogs and should be encouraged to observe infection  
333 prevention measures such as hand washing with soap and clean water after handling their  
334 animals.

335           The association between AMR and breed reported in this study is surprising. We found  
336 that terriers and herding dogs were more likely to harbor AMR *E. coli* when compared to other  
337 breed categories. This is an interesting finding that needs to be further investigated as no  
338 previous study has elucidated this.

339           One limitation of this study was the lack of data related the clinical history of the dogs  
340 from which samples were collected. This prevented us from discerning the severity of the disease  
341 the dog presented with. Further, the lack of specific information regarding prior antimicrobial  
342 use in the dogs included in the study limits the inferences that can be made regarding AMU and  
343 its relationship with subsequent development of AMR.

#### 344 **Conclusions**

345           Our findings suggest that AMR in *E. coli* in dogs could be increasing in the state of  
346 Indiana. Dogs aged more than 10 years and those aged 1 to 3 years could play a role in the  
347 spread of AMR. *E. coli* in dogs in Indiana are likely to be highly susceptible to aminoglycosides  
348 (e.g., amikacin) and to carbapenems (e.g., imipenem). The findings of this study should inform  
349 efforts aimed at addressing the AMR challenge and may prove useful in guiding small animal  
350 clinicians in the state of Indiana in choosing appropriate antimicrobials for empiric therapy.

#### 351 **Acknowledgments**

352           We thank the Integrative Data Science Initiative at Purdue University for funding this  
353 work and the Indiana Animal Disease Diagnostic Laboratory for providing the data used in these  
354 analyses.

#### 355 **References**



- 356 1. Paitan Y. Current Trends in Antimicrobial Resistance of *Escherichia coli*. Curr Top  
357 Microbiol Immunol. 2018;416: 181–211. doi:10.1007/82\_2018\_110
- 358 2. Courtice R, Sniatynski M, Rubin JE. Characterization of antimicrobial-resistant *Escherichia*  
359 *coli* causing urinary tract infections in dogs: Passive surveillance in Saskatchewan, Canada  
360 2014 to 2018. Journal of Veterinary Internal Medicine. 2021;35: 1389–1396.  
361 doi:10.1111/jvim.16103
- 362 3. LeCuyer TE, Byrne BA, Daniels JB, Diaz-Campos DV, Hammac GK, Miller CB, et al.  
363 Population Structure and Antimicrobial Resistance of Canine Uropathogenic *Escherichia*  
364 *coli*. J Clin Microbiol. 2018;56: e00788-18. doi:10.1128/JCM.00788-18
- 365 4. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the  
366 United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019 Nov.  
367 doi:10.15620/cdc:82532
- 368 5. Pomba C, Rantala M, Greko C, Baptiste KE, Catry B, van Duijkeren E, et al. Public health  
369 risk of antimicrobial resistance transfer from companion animals. J Antimicrob Chemother.  
370 2017;72: 957–968. doi:10.1093/jac/dkw481
- 371 6. Jim ER, Mark GP. Veterinary Pharmacology and Therapeutics. 9<sup>th</sup> ed. Ames, Iowa: Wiley-  
372 Blackwell, 2009.
- 373 7. WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance and World  
374 Health Organization - 2017 - Critically important antimicrobials for human medi.pdf.  
375 Available from: [https://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-](https://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-eng.pdf?sequence=1&isAllowed=y)  
376 [eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-eng.pdf?sequence=1&isAllowed=y)

- 377 8. Boerlin P, White DG. Antimicrobial Resistance and Its Epidemiology. 1st ed. In: Giguère  
378 S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 1st ed.  
379 Wiley; 2013. pp. 21–40. doi:10.1002/9781118675014.ch3
- 380 9. Wallis LJ, Szabó D, Erdélyi-Belle B, Kubinyi E. Demographic Change Across the Lifespan  
381 of Pet Dogs and Their Impact on Health Status. *Front Vet Sci.* 2018;5.  
382 doi:10.3389/fvets.2018.00200
- 383 10. Conner JG, Smith J, Erol E, Locke S, Phillips E, Carter CN, et al. Temporal trends and  
384 predictors of antimicrobial resistance among *Staphylococcus spp.* isolated from canine  
385 specimens submitted to a diagnostic laboratory. *PLoS One.* 2018;13: e0200719.  
386 doi:10.1371/journal.pone.0200719
- 387 11. Breed Standards | United Kennel Club (UKC). [cited 28 Jan 2021]. Available:  
388 <https://www.ukcdogs.com/breed-standards>
- 389 12. Sweeney MT, Lubbers BV, Schwarz S, Watts JL. Applying definitions for multidrug  
390 resistance, extensive drug resistance and pandrug resistance to clinically significant  
391 livestock and companion animal bacterial pathogens. *J Antimicrob Chemother.* 2018;73:  
392 1460–1463. doi:10.1093/jac/dky043
- 393 13. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.  
394 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an  
395 international expert proposal for interim standard definitions for acquired resistance. *Clin  
396 Microbiol Infect.* 2012;18: 268–281. doi:10.1111/j.1469-0691.2011.03570.x

- 397 14. M39-A4: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data;  
398 Approved Guideline—Fourth Edition. : 102.
- 399 15. Thungrat K, Price SB, Carpenter DM, Boothe DM. Antimicrobial susceptibility patterns of  
400 clinical *Escherichia coli* isolates from dogs and cats in the United States: January 2008  
401 through January 2013. *Veterinary Microbiology*. 2015;179: 287–295.  
402 doi:10.1016/j.vetmic.2015.06.012
- 403 16. Shea A, McCarthy R, Lindenmayer J. Therapeutic Antibiotic Use Patterns in Dogs:  
404 Observations from a Veterinary Teaching Hospital. *J Small Anim Pract*. 2011;52: 310–318.  
405 doi:10.1111/j.1748-5827.2011.01072.x
- 406 17. Awosile BB, McClure JT, Saab ME, Heider LC. Antimicrobial resistance in bacteria  
407 isolated from cats and dogs from the Atlantic Provinces, Canada from 1994-2013. *Can Vet*  
408 *J*. 2018;59: 885–893.
- 409 18. Belmar-Liberato R, Gonzalez-Canga A, Tamame-Martin P, Escribano-Salazar M.  
410 Amoxicillin and amoxicillin-clavulanic acid resistance in veterinary medicine—the situation  
411 in Europe: a review. *Veterinari Medicina*. 2011;56: 473.
- 412 19. Cummings KJ, Aprea VA, Altier C. Antimicrobial resistance trends among canine  
413 *Escherichia coli* isolates obtained from clinical samples in the northeastern USA, 2004-  
414 2011. *Can Vet J*. 2015;56: 393–398.
- 415 20. Boothe D, Smaha T, Carpenter DM, Shaheen B, Hatchcock T. Antimicrobial Resistance  
416 and Pharmacodynamics of Canine and Feline Pathogenic *E. coli* in the United States.

- 417 Journal of the American Animal Hospital Association. 2012;48: 379–389.  
418 doi:10.5326/JAAHA-MS-5805
- 419 21. De Graef EM, Decostere A, Devriese LA, Haesebrouck F. Antibiotic resistance among  
420 fecal indicator bacteria from healthy individually owned and kennel dogs. *Microb Drug*  
421 *Resist.* 2004;10: 65–69. doi:10.1089/107662904323047826
- 422 22. Nyirabahizi E, Tyson GH, Dessai U, Zhao S, Kabera C, Craey E, et al. Evaluation of  
423 *Escherichia coli* as an indicator for antimicrobial resistance in *Salmonella* recovered from  
424 the same food or animal ceca samples. *Food Control.* 2020;115: 107280.  
425 doi:10.1016/j.foodcont.2020.107280
- 426 23. Joosten P, Ceccarelli D, Odent E, Sarrazin S, Graveland H, Van Gompel L, et al.  
427 Antimicrobial Usage and Resistance in Companion Animals: A Cross-Sectional Study in  
428 Three European Countries. *Antibiotics.* 2020;9: 87. doi:10.3390/antibiotics9020087
- 429 24. Smith A, Wayne AS, Fellman CL, Rosenbaum MH. Usage patterns of carbapenem  
430 antimicrobials in dogs and cats at a veterinary tertiary care hospital. *J Vet Intern Med.*  
431 2019/05/22 ed. 2019;33: 1677–1685. doi:10.1111/jvim.15522
- 432 25. Angus JC, Jang SS, Hirsh DC. Microbiological study of transtracheal aspirates from dogs  
433 with suspected lower respiratory tract disease: 264 cases (1989-1995). *J Am Vet Med*  
434 *Assoc.* 1997;210: 55–58.
- 435 26. Oluoch AO, Kim CH, Weisiger RM, Koo HY, Siegel AM, Campbell KL, et al. Nonenteric  
436 *Escherichia coli* isolates from dogs: 674 cases (1990-1998). *J Am Vet Med Assoc.*  
437 2001;218: 381–384. doi:10.2460/javma.2001.218.381

- 438 27. Saputra S, Jordan D, Mitchell T, Wong HS, Abraham RJ, Kidsley A, et al. Antimicrobial  
439 resistance in clinical *Escherichia coli* isolated from companion animals in Australia.  
440 *Veterinary Microbiology*. 2017;211: 43–50. doi:10.1016/j.vetmic.2017.09.014
- 441 28. Schmidt VM, Pinchbeck G, McIntyre KM, Nuttall T, McEwan N, Dawson S, et al. Routine  
442 antibiotic therapy in dogs increases the detection of antimicrobial-resistant faecal  
443 *Escherichia coli*. *Journal of Antimicrobial Chemotherapy*. 2018;73: 3305–3316.  
444 doi:10.1093/jac/dky352
- 445 29. Wedley AL, Dawson S, Maddox TW, Coyne KP, Pinchbeck GL, Clegg P, et al. Carriage of  
446 antimicrobial resistant *Escherichia coli* in dogs: Prevalence, associated risk factors and  
447 molecular characteristics. *Veterinary Microbiology*. 2017;199: 23–30.  
448 doi:10.1016/j.vetmic.2016.11.017
- 449 30. Papich MG. Antibiotic Treatment of Resistant Infections in Small Animals. *Veterinary*  
450 *Clinics of North America: Small Animal Practice*. 2013;43: 1091–1107.  
451 doi:10.1016/j.cvsm.2013.04.006
- 452 31. Boothe DM, Debavalya N. Impact of Routine Antimicrobial Therapy on Canine fecal  
453 *Escherichia coli* Antimicrobial Resistance: A Pilot Study. *International Journal of Applied*  
454 *Research in Veterinary Medicine*. 2011;9: 11.
- 455 32. Ball KR, Rubin JE, Chirino-Trejo M, Dowling PM. Antimicrobial resistance and  
456 prevalence of canine uropathogens at the Western College of Veterinary Medicine  
457 Veterinary Teaching Hospital, 2002-2007. *Can Vet J*. 2008;49: 985–990.

458




Figure 1